RÉSUMÉ
Background: Chikungunya virus has recently re-emerged in India. Objectives: Assess prevalence of Chikungunya. Materials and Methods: Study conducted from April 2011 to September 2011. Two hundred and six patients (206) of both sexes (100 males and 106 females) of all age groups studied. Serum separated and CHIKV MAC IgM ELISA and Hemagglutination inhibition assay done. Results: 76 cases (36.89%) sero-positive by both the methods. Conclusion: Re-emergence and resurgence of the Chikungunya virus requires continuous monitoring.
RÉSUMÉ
Objective Through the detection of rabbit hemorrhagic disease virus( RHDV) antibody, to investigate the capacity of experimental animal quality control laboratories, so as to improve their detection proficiency.Methods According to the program approved by CNAS, the screened samples were numbered randomly and tested for their stability and homogeneity.The random samples were issued to the participant laboratories with the Standard Operation Procedure ( SOP) .The participant laboratories must submit the test reports and original records in time.The feedback results were judged by the rate of concordance with the anticipated results.Results Twenty laboratories from 14 provinces were en-rolled in the evaluation, and all of them submitted detection results on time.ELISA methods were used in 14 laboratories, and hemagglutination inhibition ( HAI) assay was used in 6 laboratories.The results of 17 laboratories were marked as pass or excellent, with a rate of pass of 85%.Conclusions The ability for detection of RHDV antibody in animal test labora-tories in China is high.The implementation of capacity testing can reflect the level of quality control laboratories.
RÉSUMÉ
Objective. To determine the safety, the immunogenicity, and the increase of pre-existing autoantibodies in patients with systemic lupus erythematosus (SLE) following influenza vaccination. Patients and Methods. Eighteen women with SLE received an inactivated influenza vaccine. Antibody titers were measured before and 4 weeks after vaccination using a standardized hemagglutination inhibition (HAI) assay. Disease activity and antinuclear autoantibodies were determined at study entry, at 4 weeks, and at 8 weeks after vaccination. Results. After vaccination, the percentage of patients with anti-hemagglutinin antibody levels increased significantly but was lower than in healthy women. Mean antibody titer of patients increased significantly but also was lower than that of controls. Both the mean of disease activity and anti-ds DNA antibody decreased significantly. Adverse effects to the vaccine were mild. Conclusions. a) Influenza vaccination appears to be safe; b). Antibody response to influenza vaccination increases significantly for all 3 influenza antigens; c) Specific antibody response is not significantly affected by treatment, age, IgG levels, or disease activity.
Objetivo. Determinar la seguridad, la respuesta de anticuerpo y el aumento de autoanticuerpos preexistentes en pacientes con lupus después de la vacunación contra influenza. Métodos. Dieciocho mujeres con LES recibieron vacuna contra influenza inactivada. Se determinaron los títulos de anticuerpos antiinfluenza (prueba de inhibición de la hemaglutinación) antes y a las cuatro semanas después de la vacunación. Antes, a las cuatro y ocho semanas se midieron la actividad de la enfermedad y autoanticuerpos antinucleares. Resultados. Después de la vacunación, el porcentaje de pacientes con LES con títulos de anticuerpos antihemaglutinina aumentaron significativamente pero fueron bajos comparado con las mujeres sanas. La media de títulos de anticuerpos antiinfluenza aumentó significativamente a las cuatro semanas, pero fue más bajo que en los controles. La media de la actividad de la enfermedad y de anticuerpos antiDNA disminuyó significativamente. Los efectos colaterales fueron leves. Conclusiones. a) La vacuna contra influenza es segura; b) La respuesta de anticuerpos después de la vacunación aumenta significativamente; c) No hay correlación significativa entre la respuesta de anticuerpo con la edad, tratamiento, niveles de IgG o con la actividad de la enfermedad.